Day: January 19, 2026

HONG KONG, Jan. 18, 2026 (GLOBE NEWSWIRE) — FTI Consulting, Inc. (NYSE: FCN) today announced the appointment of Speed Liu as a Senior Managing Director in the Business Transformation practice in Asia within the firm’s Corporate Finance & Restructuring segment. Mr. Liu, who is based in Hong Kong, joins FTI Consulting with more than 20 years of experience in private equity driving growth strategies, turnaround plans and cost optimization initiatives. He has substantial expertise advising on buyout transactions, business transformation and transactions across the consumer, service and industrials sectors. In his role at FTI Consulting, Mr. Liu will support private equity and corporate clients in Asia and abroad with portfolio transformation, transactions, exit readiness and maximizing value creation. His appointment reinforces...

Approval Label May Include Opioid Reduction NEW YORK, Jan. 18, 2026 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided feedback received from the U.S. Food & Drug Administration (FDA) on potential filing of a Biologics License Application (BLA) for its allogeneic cell therapy product rexlemestrocel-L in patients with chronic discogenic low back pain (CLBP). This follows FDA’s Type B meeting review of data from Mesoblast’s first randomized controlled Phase 3 trial (MSB-DR003) on pain reduction and relationship to decreased use or elimination of opioids for up to three years following a single rexlemestrocel-L administration. Mesoblast is seeking FDA approval for rexlemestrocel-L based on reduction in CLBP through 12 months....